Literature DB >> 24799992

Melatonin attenuates cisplatin-induced HepG2 cell death via the regulation of mTOR and ERCC1 expressions.

Kangsadarn Bennukul1, Sucha Numkliang1, Vijittra Leardkamolkarn1.   

Abstract

AIM: To elucidate the effects of melatonin on cisplatin-induced hepatocellular carcinoma (HepG2) cell death and to identify potential cross-talk pathways.
METHODS: Hepatocellular carcinoma HepG2 cells were treated with melatonin and/or cisplatin for 24 to 48 h. Cell viability and the 50% cytotoxic concentration (CC50) were calculated by MTT assays. The effects and intracellular events induced by the selected concentrations of melatonin (1 mmol/L) and cisplatin (20 μmol/L) were investigated. Cell death and survival detection were primarily evaluated using a fluorescence microscope to assess 4',6 diamideno-2-phenylindol DNA staining and acridine orange lysosome staining and then further analyzed with immunocytochemistry using an anti-LC3 antibody. The potential molecular responses mediated by melatonin against cisplatin after the combined treatment were investigated by reverse transcription-polymerase chains reaction and Western blot analyses of the genes and proteins associated with cell survival and death. A cell cycle analysis was performed using a flow cytometry assay.
RESULTS: Melatonin had a concentration-dependent effect on HepG2 cell viability. At 1 mmol/L, melatonin significantly increased the cell viability percentage and decreased reactive oxygen species production due to cisplatin. Melatonin reduced cisplatin-induced cell death, decreasing phosphorylated p53 apoptotic protein, cleaved caspase 3 and Bax levels but increasing anti-apoptotic Bcl-2 gene and protein expression. When combined with cisplatin, melatonin induced S phase (DNA synthesis) cell cycle arrest and promoted autophagic events in HepG2 cells. Melatonin also had a concentration-dependent effect on Beclin-1 and its autophagic regulator mammalian target of rapamycin (mTOR) as well as the DNA excision repair cross complementary 1 (ERCC1) protein. The expression levels of these proteins were altered in HepG2 cells during cisplatin or melatonin treatment alone. In the combination treatment, melatonin reversed the effects of cisplatin by suppressing the over-expression of mTOR and ERCC 1 and enhancing the expression levels of Beclin-1 and microtubule-associated protein-light chain3-II, leading to intracellular autophagosome progression.
CONCLUSION: Melatonin attenuated cisplatin-induced cell death in HepG2 cells via a counter-balance between the roles of apoptotic- and autophagy-related proteins.

Entities:  

Keywords:  Autophagy; Cisplatin; Excision repair cross complementary 1; Hepatocellular carcinoma; Mammalian target of rapamycin; Melatonin

Year:  2014        PMID: 24799992      PMCID: PMC4009479          DOI: 10.4254/wjh.v6.i4.230

Source DB:  PubMed          Journal:  World J Hepatol


  42 in total

Review 1.  A review of the multiple actions of melatonin on the immune system.

Authors:  Antonio Carrillo-Vico; Juan M Guerrero; Patricia J Lardone; Russel J Reiter
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

Review 2.  Effects of melatonin on vertebrate circadian systems.

Authors:  V M Cassone
Journal:  Trends Neurosci       Date:  1990-11       Impact factor: 13.837

Review 3.  How nucleotide excision repair protects against cancer.

Authors:  E C Friedberg
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

4.  Melatonin regulation of antioxidant enzyme gene expression.

Authors:  J C Mayo; R M Sainz; I Antoli; F Herrera; V Martin; C Rodriguez
Journal:  Cell Mol Life Sci       Date:  2002-10       Impact factor: 9.261

5.  Autophagy reduces acute ethanol-induced hepatotoxicity and steatosis in mice.

Authors:  Wen-Xing Ding; Min Li; Xiaoyun Chen; Hong-Min Ni; Chih-Wen Lin; Wentao Gao; Binfeng Lu; Donna B Stolz; Dahn L Clemens; Xiao-Ming Yin
Journal:  Gastroenterology       Date:  2010-07-23       Impact factor: 22.682

Review 6.  p53: traffic cop at the crossroads of DNA repair and recombination.

Authors:  Sagar Sengupta; Curtis C Harris
Journal:  Nat Rev Mol Cell Biol       Date:  2005-01       Impact factor: 94.444

7.  Melatonin promotes osteoblastic differentiation through the BMP/ERK/Wnt signaling pathways.

Authors:  Ki-Ho Park; Jong Won Kang; Eun-Man Lee; Jae Sik Kim; Yun Hee Rhee; Minseok Kim; Soo Jin Jeong; Young Guk Park; Sung Hoon Kim
Journal:  J Pineal Res       Date:  2011-04-07       Impact factor: 13.007

Review 8.  To die or not to die: how does p53 decide?

Authors:  Elizabeth A Slee; Daniel J O'Connor; Xin Lu
Journal:  Oncogene       Date:  2004-04-12       Impact factor: 9.867

9.  Melatonin as an antibiotic: new insights into the actions of this ubiquitous molecule.

Authors:  Omer Faruk Tekbas; Recai Ogur; Ahmet Korkmaz; Abdullah Kilic; Russel J Reiter
Journal:  J Pineal Res       Date:  2008-03       Impact factor: 13.007

10.  A long-term survival case of adult undifferentiated embryonal sarcoma of liver.

Authors:  Keita Noguchi; Hideki Yokoo; Kazuaki Nakanishi; Tatsuhiko Kakisaka; Yosuke Tsuruga; Hirofumi Kamachi; Michiaki Matsushita; Toshiya Kamiyama
Journal:  World J Surg Oncol       Date:  2012-04-27       Impact factor: 2.754

View more
  13 in total

1.  Melatonin potentiates cisplatin-induced apoptosis and cell cycle arrest in human lung adenocarcinoma cells.

Authors:  P Plaimee; N Weerapreeyakul; S Barusrux; N P Johns
Journal:  Cell Prolif       Date:  2015-02       Impact factor: 6.831

2.  Melatonin increases the effect of 5-fluorouracil-based chemotherapy in human colorectal adenocarcinoma cells in vitro.

Authors:  Roberto Pariente; Ignacio Bejarano; Ana Beatriz Rodríguez; José Antonio Pariente; Javier Espino
Journal:  Mol Cell Biochem       Date:  2017-08-17       Impact factor: 3.396

3.  An integrative assessment to determine the sediment toxicity of Kaohsiung Harbor in Taiwan: combining chemical analysis and cytotoxicity assay.

Authors:  Yun-Ru Ju; Chih-Feng Chen; Chiu-Wen Chen; Mei-Ling Tsai; Jia-Ching Wu; Cheng-Di Dong
Journal:  Environ Sci Pollut Res Int       Date:  2019-03-27       Impact factor: 4.223

4.  Triazolyl Ru(II), Os(II), and Ir(III) complexes as potential HIV-1 inhibitors.

Authors:  Brandon Putterill; Charles Rono; Banothile Makhubela; Debra Meyer; Ntombenhle Gama
Journal:  Biometals       Date:  2022-06-14       Impact factor: 3.378

5.  Inhibition of RORγt activity and Th17 differentiation by a set of novel compounds.

Authors:  Qingfeng Ding; Mei Zhao; Chuan Bai; Bolan Yu; Zhaofeng Huang
Journal:  BMC Immunol       Date:  2015-05-29       Impact factor: 3.615

Review 6.  Utilizing Melatonin to Alleviate Side Effects of Chemotherapy: A Potentially Good Partner for Treating Cancer with Ageing.

Authors:  Zhiqiang Ma; Liqun Xu; Dong Liu; Xiaoyan Zhang; Shouyin Di; Weimiao Li; Jiao Zhang; Russel J Reiter; Jing Han; Xiaofei Li; Xiaolong Yan
Journal:  Oxid Med Cell Longev       Date:  2020-05-21       Impact factor: 6.543

7.  A newly isolated strain of Halomonas sp. (HA1) exerts anticancer potential via induction of apoptosis and G2/M arrest in hepatocellular carcinoma (HepG2) cell line.

Authors:  Islam M El-Garawani; Sabha M El-Sabbagh; Nasser H Abbas; Hany S Ahmed; Omaima A Eissa; Doaa M Abo-Atya; Shaden A M Khalifa; Hesham R El-Seedi
Journal:  Sci Rep       Date:  2020-08-21       Impact factor: 4.379

8.  Combinatorial Treatment of Birinapant and Zosuquidar Enhances Effective Control of HBV Replication In Vivo.

Authors:  Emma Morrish; Liana Mackiewicz; Natasha Silke; Marc Pellegrini; John Silke; Gabriela Brumatti; Gregor Ebert
Journal:  Viruses       Date:  2020-08-17       Impact factor: 5.048

Review 9.  Promising Antineoplastic Actions of Melatonin.

Authors:  Gaia Favero; Enrico Moretti; Francesca Bonomini; Russel J Reiter; Luigi Fabrizio Rodella; Rita Rezzani
Journal:  Front Pharmacol       Date:  2018-10-16       Impact factor: 5.810

10.  Melatonin Regulates Cisplatin Resistance and Glucose Metabolism Through Hippo Signaling in Hepatocellular Carcinoma Cells.

Authors:  Lina Mi; Hongyu Kuang
Journal:  Cancer Manag Res       Date:  2020-03-12       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.